| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 61 | 2013 | 347 | 4.580 |
Why?
|
| Polymorphism, Single Nucleotide | 83 | 2014 | 2484 | 3.820 |
Why?
|
| Genetic Linkage | 69 | 2012 | 613 | 3.340 |
Why?
|
| Genetic Predisposition to Disease | 81 | 2014 | 2465 | 3.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 68 | 2013 | 1229 | 3.070 |
Why?
|
| Genome-Wide Association Study | 59 | 2014 | 1763 | 2.910 |
Why?
|
| Influenza A virus | 43 | 2013 | 172 | 2.800 |
Why?
|
| Genetic Variation | 44 | 2014 | 1416 | 2.280 |
Why?
|
| Influenza Vaccines | 26 | 2012 | 168 | 2.240 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 22 | 2011 | 63 | 2.230 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 22 | 2013 | 87 | 1.990 |
Why?
|
| Calpain | 20 | 2006 | 113 | 1.910 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 21 | 2013 | 112 | 1.840 |
Why?
|
| Chromosome Mapping | 58 | 2013 | 1051 | 1.830 |
Why?
|
| Pharmacogenetics | 18 | 2014 | 456 | 1.630 |
Why?
|
| Models, Genetic | 34 | 2014 | 970 | 1.550 |
Why?
|
| Disease Outbreaks | 16 | 2013 | 147 | 1.460 |
Why?
|
| Quantitative Trait Loci | 21 | 2013 | 630 | 1.430 |
Why?
|
| Polymorphism, Genetic | 41 | 2014 | 826 | 1.430 |
Why?
|
| Genome, Human | 34 | 2014 | 823 | 1.380 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 19 | 2011 | 82 | 1.360 |
Why?
|
| Humans | 350 | 2014 | 93132 | 1.240 |
Why?
|
| Genotype | 56 | 2013 | 1866 | 1.230 |
Why?
|
| Linkage Disequilibrium | 26 | 2013 | 478 | 0.970 |
Why?
|
| Reassortant Viruses | 9 | 2011 | 23 | 0.950 |
Why?
|
| Alleles | 37 | 2013 | 1139 | 0.940 |
Why?
|
| Influenza in Birds | 11 | 2013 | 29 | 0.930 |
Why?
|
| Computational Biology | 15 | 2014 | 581 | 0.920 |
Why?
|
| Pedigree | 43 | 2011 | 962 | 0.880 |
Why?
|
| Diabetes Mellitus, Type 1 | 12 | 2013 | 590 | 0.870 |
Why?
|
| Insulin | 19 | 2009 | 1184 | 0.860 |
Why?
|
| Chromosomes, Human, Pair 15 | 7 | 2010 | 65 | 0.810 |
Why?
|
| Haplotypes | 29 | 2011 | 647 | 0.800 |
Why?
|
| Chromosomes, Human, Pair 6 | 8 | 2013 | 127 | 0.780 |
Why?
|
| Obsessive-Compulsive Disorder | 6 | 2013 | 160 | 0.770 |
Why?
|
| Female | 159 | 2014 | 48542 | 0.770 |
Why?
|
| Gene Frequency | 30 | 2013 | 700 | 0.760 |
Why?
|
| Stuttering | 10 | 2006 | 22 | 0.760 |
Why?
|
| Antibodies, Viral | 14 | 2011 | 320 | 0.750 |
Why?
|
| Chromosomes, Human, Pair 11 | 7 | 2006 | 106 | 0.740 |
Why?
|
| Phenotype | 37 | 2014 | 2545 | 0.740 |
Why?
|
| Genomics | 10 | 2014 | 848 | 0.690 |
Why?
|
| Male | 136 | 2014 | 44355 | 0.680 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2014 | 636 | 0.680 |
Why?
|
| Antineoplastic Agents | 11 | 2014 | 2301 | 0.660 |
Why?
|
| Gene Expression Profiling | 15 | 2014 | 1517 | 0.660 |
Why?
|
| Asthma | 14 | 2014 | 1039 | 0.650 |
Why?
|
| Quantitative Trait, Heritable | 9 | 2013 | 125 | 0.620 |
Why?
|
| Autistic Disorder | 5 | 2009 | 150 | 0.620 |
Why?
|
| Case-Control Studies | 25 | 2014 | 1925 | 0.610 |
Why?
|
| Orthomyxoviridae Infections | 8 | 2013 | 56 | 0.600 |
Why?
|
| Lod Score | 17 | 2007 | 152 | 0.600 |
Why?
|
| Epistasis, Genetic | 4 | 2010 | 90 | 0.580 |
Why?
|
| MicroRNAs | 6 | 2014 | 581 | 0.580 |
Why?
|
| Polycystic Ovary Syndrome | 7 | 2009 | 193 | 0.580 |
Why?
|
| Antiviral Agents | 12 | 2010 | 364 | 0.570 |
Why?
|
| Chromosomes, Human, Pair 2 | 11 | 2010 | 85 | 0.570 |
Why?
|
| Cell Line | 23 | 2014 | 2458 | 0.570 |
Why?
|
| Nerve Tissue Proteins | 7 | 2012 | 501 | 0.560 |
Why?
|
| Genetic Markers | 30 | 2007 | 469 | 0.540 |
Why?
|
| Gene Expression Regulation | 12 | 2014 | 1980 | 0.540 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 12 | 2011 | 691 | 0.530 |
Why?
|
| Polymerase Chain Reaction | 12 | 2011 | 888 | 0.530 |
Why?
|
| Molecular Sequence Data | 39 | 2011 | 2889 | 0.530 |
Why?
|
| Polymorphism, Restriction Fragment Length | 21 | 2005 | 145 | 0.520 |
Why?
|
| Child | 55 | 2014 | 7273 | 0.520 |
Why?
|
| Receptors, Virus | 5 | 2011 | 73 | 0.520 |
Why?
|
| Obesity | 9 | 2010 | 1014 | 0.520 |
Why?
|
| Databases, Genetic | 8 | 2012 | 283 | 0.500 |
Why?
|
| Gene Dosage | 4 | 2011 | 211 | 0.500 |
Why?
|
| Adult | 89 | 2013 | 27849 | 0.490 |
Why?
|
| Base Sequence | 32 | 2011 | 2207 | 0.480 |
Why?
|
| Islets of Langerhans | 8 | 2006 | 556 | 0.480 |
Why?
|
| Tourette Syndrome | 2 | 2013 | 24 | 0.470 |
Why?
|
| Ferrets | 13 | 2013 | 49 | 0.460 |
Why?
|
| Genes, Viral | 12 | 2008 | 101 | 0.450 |
Why?
|
| Transcriptome | 5 | 2014 | 762 | 0.440 |
Why?
|
| Adolescent | 49 | 2013 | 9550 | 0.440 |
Why?
|
| Neuraminidase | 10 | 2012 | 44 | 0.440 |
Why?
|
| ATP-Binding Cassette Transporters | 6 | 2014 | 140 | 0.430 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2006 | 83 | 0.430 |
Why?
|
| Genes | 3 | 2011 | 256 | 0.420 |
Why?
|
| Receptors, Drug | 5 | 2007 | 51 | 0.400 |
Why?
|
| Breast Neoplasms | 10 | 2014 | 3155 | 0.400 |
Why?
|
| Alternative Splicing | 4 | 2012 | 220 | 0.400 |
Why?
|
| Mexican Americans | 10 | 2013 | 70 | 0.390 |
Why?
|
| Gene Expression | 7 | 2012 | 1304 | 0.390 |
Why?
|
| Virus Replication | 10 | 2012 | 284 | 0.390 |
Why?
|
| Influenza A Virus, H2N2 Subtype | 4 | 2011 | 10 | 0.390 |
Why?
|
| Algorithms | 9 | 2014 | 1948 | 0.390 |
Why?
|
| Disease | 2 | 2013 | 91 | 0.390 |
Why?
|
| Nucleoproteins | 4 | 2011 | 20 | 0.390 |
Why?
|
| Animals | 57 | 2013 | 27973 | 0.390 |
Why?
|
| Exons | 6 | 2012 | 447 | 0.380 |
Why?
|
| Influenza B virus | 7 | 2010 | 33 | 0.380 |
Why?
|
| Orthomyxoviridae | 5 | 2013 | 46 | 0.380 |
Why?
|
| Genetic Diseases, Inborn | 5 | 2011 | 101 | 0.380 |
Why?
|
| Bipolar Disorder | 7 | 2012 | 398 | 0.380 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 5 | 2007 | 121 | 0.380 |
Why?
|
| Blood Glucose | 8 | 2013 | 866 | 0.380 |
Why?
|
| Pandemics | 3 | 2011 | 873 | 0.380 |
Why?
|
| Software | 12 | 2014 | 669 | 0.380 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2013 | 52 | 0.370 |
Why?
|
| Child, Preschool | 33 | 2013 | 3781 | 0.370 |
Why?
|
| Fibrillar Collagens | 1 | 2012 | 10 | 0.370 |
Why?
|
| Multifactorial Inheritance | 4 | 2014 | 202 | 0.370 |
Why?
|
| Potassium Channels | 6 | 2007 | 346 | 0.370 |
Why?
|
| Middle Aged | 63 | 2014 | 27535 | 0.360 |
Why?
|
| Drug Resistance, Viral | 7 | 2012 | 37 | 0.360 |
Why?
|
| Tamoxifen | 2 | 2013 | 170 | 0.360 |
Why?
|
| Amino Acid Sequence | 22 | 2011 | 1994 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2014 | 1339 | 0.350 |
Why?
|
| Seasons | 9 | 2013 | 239 | 0.340 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2011 | 18 | 0.340 |
Why?
|
| Receptors, GABA-A | 2 | 2009 | 35 | 0.340 |
Why?
|
| eIF-2 Kinase | 1 | 2011 | 50 | 0.340 |
Why?
|
| Mutation, Missense | 6 | 2011 | 296 | 0.340 |
Why?
|
| Diabetic Retinopathy | 2 | 2012 | 79 | 0.330 |
Why?
|
| Virology | 1 | 2011 | 13 | 0.330 |
Why?
|
| Vaccination | 6 | 2009 | 303 | 0.330 |
Why?
|
| Cell Proliferation | 4 | 2012 | 1732 | 0.330 |
Why?
|
| Hyperglycemia | 3 | 2012 | 178 | 0.330 |
Why?
|
| Carboplatin | 6 | 2011 | 321 | 0.330 |
Why?
|
| Population Groups | 1 | 2010 | 42 | 0.330 |
Why?
|
| Phosphoproteins | 4 | 2009 | 258 | 0.320 |
Why?
|
| Diabetes Mellitus | 4 | 2007 | 762 | 0.320 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 3 | 2003 | 8 | 0.320 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 55 | 0.320 |
Why?
|
| Virus Attachment | 1 | 2010 | 6 | 0.320 |
Why?
|
| DNA | 12 | 2010 | 1260 | 0.320 |
Why?
|
| Genetic Testing | 8 | 2012 | 564 | 0.320 |
Why?
|
| Cisplatin | 5 | 2013 | 567 | 0.320 |
Why?
|
| Leukocytes | 2 | 2014 | 210 | 0.320 |
Why?
|
| Sex Factors | 9 | 2011 | 1102 | 0.320 |
Why?
|
| Antigens, Viral | 8 | 2008 | 122 | 0.310 |
Why?
|
| Biostatistics | 1 | 2010 | 21 | 0.310 |
Why?
|
| Models, Statistical | 4 | 2012 | 584 | 0.310 |
Why?
|
| Infant | 22 | 2013 | 3156 | 0.300 |
Why?
|
| United States | 30 | 2013 | 7581 | 0.300 |
Why?
|
| Population Surveillance | 5 | 2012 | 212 | 0.300 |
Why?
|
| Hemagglutinins, Viral | 9 | 2000 | 38 | 0.300 |
Why?
|
| Germ-Line Mutation | 5 | 2012 | 381 | 0.300 |
Why?
|
| Warfarin | 3 | 2013 | 106 | 0.300 |
Why?
|
| Neoplasms | 7 | 2014 | 3168 | 0.300 |
Why?
|
| Cell Line, Tumor | 12 | 2014 | 2757 | 0.290 |
Why?
|
| Chickens | 4 | 2011 | 193 | 0.290 |
Why?
|
| Disease Susceptibility | 10 | 2011 | 220 | 0.290 |
Why?
|
| Platinum | 2 | 2014 | 67 | 0.290 |
Why?
|
| Virus Internalization | 1 | 2009 | 45 | 0.290 |
Why?
|
| Hemagglutination Inhibition Tests | 10 | 2009 | 42 | 0.280 |
Why?
|
| RNA, Viral | 12 | 2009 | 285 | 0.280 |
Why?
|
| Founder Effect | 7 | 2001 | 106 | 0.280 |
Why?
|
| Pregnancy Complications | 3 | 2012 | 350 | 0.280 |
Why?
|
| Aged | 39 | 2013 | 20395 | 0.280 |
Why?
|
| Cohort Studies | 17 | 2014 | 3044 | 0.270 |
Why?
|
| Hyperinsulinism | 2 | 2010 | 44 | 0.270 |
Why?
|
| Immunization Schedule | 2 | 2009 | 23 | 0.270 |
Why?
|
| Liver | 6 | 2013 | 1206 | 0.270 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2012 | 422 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 20 | 4 | 2004 | 32 | 0.260 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 44 | 0.260 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 31 | 0.260 |
Why?
|
| Psychiatry | 2 | 2008 | 88 | 0.250 |
Why?
|
| Diabetes Complications | 4 | 2012 | 167 | 0.250 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 75 | 0.250 |
Why?
|
| Day Care, Medical | 4 | 1999 | 10 | 0.250 |
Why?
|
| Pancreas | 2 | 2010 | 256 | 0.250 |
Why?
|
| Drug Discovery | 2 | 2012 | 113 | 0.250 |
Why?
|
| Risk | 9 | 2012 | 651 | 0.250 |
Why?
|
| Anticoagulants | 3 | 2013 | 455 | 0.250 |
Why?
|
| Adamantane | 3 | 2008 | 6 | 0.240 |
Why?
|
| Phylogeny | 12 | 2012 | 1268 | 0.240 |
Why?
|
| Abdominal Fat | 1 | 2006 | 13 | 0.240 |
Why?
|
| Family | 7 | 2005 | 319 | 0.240 |
Why?
|
| Mutation | 19 | 2011 | 4265 | 0.240 |
Why?
|
| Systems Biology | 2 | 2014 | 47 | 0.240 |
Why?
|
| Coronary Angiography | 1 | 2007 | 232 | 0.240 |
Why?
|
| Membrane Transport Proteins | 4 | 2009 | 169 | 0.240 |
Why?
|
| Swine | 6 | 2013 | 585 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 11 | 2013 | 1099 | 0.240 |
Why?
|
| Cholesterol | 2 | 2003 | 364 | 0.230 |
Why?
|
| Insulin Resistance | 5 | 2012 | 379 | 0.230 |
Why?
|
| Transcription Factors | 8 | 2012 | 1687 | 0.230 |
Why?
|
| Glucuronosyltransferase | 2 | 2012 | 178 | 0.230 |
Why?
|
| Amino Acid Substitution | 7 | 2011 | 331 | 0.230 |
Why?
|
| Body Mass Index | 9 | 2013 | 806 | 0.230 |
Why?
|
| Neuroblastoma | 2 | 2014 | 394 | 0.220 |
Why?
|
| Research Design | 8 | 2012 | 620 | 0.220 |
Why?
|
| Leucine | 2 | 2003 | 56 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2013 | 54 | 0.220 |
Why?
|
| Vaccines, Attenuated | 6 | 2011 | 52 | 0.220 |
Why?
|
| Computer Simulation | 9 | 2012 | 1120 | 0.220 |
Why?
|
| Biomarkers, Tumor | 3 | 2014 | 1660 | 0.220 |
Why?
|
| Membrane Glycoproteins | 4 | 2009 | 443 | 0.220 |
Why?
|
| Schizophrenia | 2 | 2006 | 530 | 0.220 |
Why?
|
| Molecular Epidemiology | 3 | 2011 | 57 | 0.220 |
Why?
|
| Hong Kong | 12 | 2007 | 45 | 0.220 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2011 | 104 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2010 | 113 | 0.210 |
Why?
|
| Chick Embryo | 5 | 2010 | 174 | 0.210 |
Why?
|
| HLA Antigens | 6 | 2004 | 228 | 0.210 |
Why?
|
| Pancreatitis | 2 | 1997 | 94 | 0.210 |
Why?
|
| Signal Transduction | 6 | 2013 | 3497 | 0.210 |
Why?
|
| Genetic Loci | 3 | 2013 | 260 | 0.200 |
Why?
|
| Japan | 10 | 2006 | 299 | 0.200 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 25 | 0.200 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2003 | 5 | 0.200 |
Why?
|
| Risk Factors | 20 | 2012 | 5900 | 0.200 |
Why?
|
| Meta-Analysis as Topic | 3 | 2012 | 83 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 1 | 4 | 2007 | 102 | 0.200 |
Why?
|
| Linear Models | 5 | 2013 | 413 | 0.200 |
Why?
|
| Therapeutics | 1 | 2013 | 13 | 0.200 |
Why?
|
| Femoral Neck Fractures | 1 | 2013 | 10 | 0.200 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 47 | 0.200 |
Why?
|
| Vitamin K | 1 | 2013 | 25 | 0.200 |
Why?
|
| Sulfonylurea Receptors | 5 | 2007 | 49 | 0.200 |
Why?
|
| Influenza A Virus, H7N3 Subtype | 1 | 2013 | 3 | 0.200 |
Why?
|
| Viral Tropism | 1 | 2013 | 4 | 0.200 |
Why?
|
| Attitude of Health Personnel | 2 | 2008 | 648 | 0.200 |
Why?
|
| Conjunctivitis | 1 | 2013 | 6 | 0.190 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 68 | 0.190 |
Why?
|
| Chromosomes, Artificial, Yeast | 5 | 1996 | 36 | 0.190 |
Why?
|
| Hearing Loss | 1 | 2013 | 64 | 0.190 |
Why?
|
| Reproducibility of Results | 8 | 2014 | 2705 | 0.190 |
Why?
|
| Genome, Viral | 5 | 2009 | 77 | 0.190 |
Why?
|
| Respiratory Mucosa | 3 | 2013 | 90 | 0.190 |
Why?
|
| DNA Copy Number Variations | 2 | 2011 | 192 | 0.190 |
Why?
|
| Triglycerides | 1 | 2003 | 231 | 0.190 |
Why?
|
| Pregnancy | 12 | 2013 | 3128 | 0.190 |
Why?
|
| Likelihood Functions | 8 | 2006 | 256 | 0.190 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 44 | 0.190 |
Why?
|
| Glucose Tolerance Test | 7 | 2013 | 233 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 6 | 2007 | 305 | 0.190 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 53 | 0.190 |
Why?
|
| Mixed Function Oxygenases | 2 | 2013 | 68 | 0.190 |
Why?
|
| Universities | 1 | 2013 | 150 | 0.190 |
Why?
|
| Vaccines, Inactivated | 6 | 2011 | 32 | 0.180 |
Why?
|
| Mental Disorders | 3 | 2008 | 451 | 0.180 |
Why?
|
| Methyltransferases | 1 | 2013 | 212 | 0.180 |
Why?
|
| Privacy | 1 | 2012 | 20 | 0.180 |
Why?
|
| Time Factors | 11 | 2014 | 5380 | 0.180 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2004 | 64 | 0.180 |
Why?
|
| DNA Primers | 11 | 2002 | 528 | 0.180 |
Why?
|
| Postmenopause | 1 | 2012 | 106 | 0.180 |
Why?
|
| Nitriles | 1 | 2012 | 154 | 0.180 |
Why?
|
| Sample Size | 1 | 2012 | 128 | 0.180 |
Why?
|
| Macular Edema | 1 | 2012 | 41 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2006 | 51 | 0.180 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 240 | 0.180 |
Why?
|
| Epithelial Cells | 3 | 2013 | 700 | 0.180 |
Why?
|
| Cross Protection | 1 | 2011 | 11 | 0.180 |
Why?
|
| Metabolic Syndrome | 4 | 2008 | 122 | 0.180 |
Why?
|
| Temperature | 3 | 2013 | 421 | 0.180 |
Why?
|
| Triazoles | 1 | 2012 | 110 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 6 | 2011 | 891 | 0.170 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 184 | 0.170 |
Why?
|
| Carrier Proteins | 4 | 2009 | 660 | 0.170 |
Why?
|
| Ducks | 3 | 2009 | 8 | 0.170 |
Why?
|
| Young Adult | 13 | 2013 | 6922 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 151 | 0.170 |
Why?
|
| Glutathione Transferase | 2 | 2008 | 115 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2013 | 289 | 0.170 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 21 | 0.170 |
Why?
|
| Poultry | 6 | 2009 | 22 | 0.170 |
Why?
|
| Mineral Fibers | 1 | 2011 | 2 | 0.170 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 556 | 0.170 |
Why?
|
| Europe | 7 | 2008 | 338 | 0.170 |
Why?
|
| HLA-DR Antigens | 5 | 1991 | 56 | 0.170 |
Why?
|
| Information Dissemination | 1 | 2012 | 124 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 244 | 0.170 |
Why?
|
| Nuclear Family | 8 | 2002 | 92 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2014 | 477 | 0.160 |
Why?
|
| Viral Proteins | 4 | 2012 | 247 | 0.160 |
Why?
|
| Virulence | 6 | 2009 | 273 | 0.160 |
Why?
|
| DNA-Binding Proteins | 5 | 2012 | 1231 | 0.160 |
Why?
|
| TCF Transcription Factors | 1 | 2010 | 24 | 0.160 |
Why?
|
| Models, Molecular | 4 | 2012 | 1353 | 0.160 |
Why?
|
| Polysaccharides | 2 | 2011 | 94 | 0.160 |
Why?
|
| Asparaginase | 1 | 2010 | 35 | 0.160 |
Why?
|
| Mice | 18 | 2013 | 12230 | 0.160 |
Why?
|
| Coronaviridae Infections | 2 | 1990 | 6 | 0.160 |
Why?
|
| Environmental Pollutants | 1 | 2011 | 56 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 38 | 0.160 |
Why?
|
| Age Factors | 10 | 2014 | 1898 | 0.160 |
Why?
|
| Cat Diseases | 2 | 1990 | 19 | 0.160 |
Why?
|
| Pregnancy in Diabetics | 1 | 2010 | 41 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2013 | 99 | 0.160 |
Why?
|
| Receptors, AMPA | 1 | 2010 | 68 | 0.160 |
Why?
|
| Peritonitis | 2 | 1990 | 28 | 0.160 |
Why?
|
| Cluster Analysis | 5 | 2010 | 391 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 202 | 0.150 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2010 | 49 | 0.150 |
Why?
|
| Neutralization Tests | 6 | 2009 | 72 | 0.150 |
Why?
|
| Infant, Newborn | 9 | 2013 | 2427 | 0.150 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 7 | 1991 | 28 | 0.150 |
Why?
|
| Chromosomes, Human | 4 | 2008 | 65 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 555 | 0.150 |
Why?
|
| Environmental Exposure | 2 | 2011 | 355 | 0.150 |
Why?
|
| Birds | 5 | 2009 | 172 | 0.150 |
Why?
|
| Receptor, Insulin | 5 | 2002 | 60 | 0.150 |
Why?
|
| Texas | 6 | 2011 | 131 | 0.150 |
Why?
|
| RNA-Binding Proteins | 3 | 2013 | 306 | 0.150 |
Why?
|
| Inheritance Patterns | 3 | 2014 | 53 | 0.150 |
Why?
|
| Nuclear Proteins | 4 | 2006 | 740 | 0.150 |
Why?
|
| Alzheimer Disease | 3 | 2010 | 600 | 0.140 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1996 | 128 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2013 | 457 | 0.140 |
Why?
|
| DNA, Satellite | 2 | 1995 | 20 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 538 | 0.140 |
Why?
|
| Antigenic Variation | 4 | 2012 | 28 | 0.140 |
Why?
|
| Folic Acid | 1 | 2009 | 62 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2013 | 432 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2014 | 2020 | 0.140 |
Why?
|
| Poultry Diseases | 3 | 2009 | 11 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 270 | 0.140 |
Why?
|
| Aged, 80 and over | 12 | 2013 | 7039 | 0.140 |
Why?
|
| Complex Mixtures | 1 | 2008 | 6 | 0.140 |
Why?
|
| Cognition Disorders | 2 | 2010 | 235 | 0.140 |
Why?
|
| Penetrance | 4 | 2013 | 49 | 0.140 |
Why?
|
| Mexico | 4 | 2013 | 72 | 0.140 |
Why?
|
| Bayes Theorem | 3 | 2014 | 403 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 101 | 0.130 |
Why?
|
| Lipids | 1 | 2009 | 277 | 0.130 |
Why?
|
| Viral Plaque Assay | 3 | 2011 | 17 | 0.130 |
Why?
|
| Birth Weight | 2 | 2013 | 148 | 0.130 |
Why?
|
| North America | 4 | 2008 | 197 | 0.130 |
Why?
|
| Trans-Activators | 1 | 2010 | 439 | 0.130 |
Why?
|
| Dogs | 5 | 2011 | 632 | 0.130 |
Why?
|
| Global Health | 5 | 2012 | 207 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 47 | 0.130 |
Why?
|
| Bias | 2 | 2005 | 136 | 0.130 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2002 | 33 | 0.130 |
Why?
|
| Heat-Shock Proteins | 2 | 2008 | 177 | 0.130 |
Why?
|
| Apolipoproteins C | 1 | 1996 | 5 | 0.130 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2007 | 30 | 0.130 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1997 | 70 | 0.120 |
Why?
|
| Excitatory Amino Acid Transporter 3 | 1 | 2006 | 6 | 0.120 |
Why?
|
| Models, Biological | 4 | 2011 | 1768 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2005 | 64 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2008 | 304 | 0.120 |
Why?
|
| Genetics, Population | 6 | 2008 | 438 | 0.120 |
Why?
|
| Viral Structural Proteins | 2 | 2007 | 17 | 0.120 |
Why?
|
| Glycogen Synthase | 1 | 1996 | 22 | 0.120 |
Why?
|
| Biological Evolution | 4 | 2008 | 1019 | 0.120 |
Why?
|
| Vaccines, Synthetic | 2 | 2011 | 55 | 0.120 |
Why?
|
| Hypertriglyceridemia | 1 | 1996 | 71 | 0.120 |
Why?
|
| Viral Core Proteins | 3 | 2013 | 23 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 556 | 0.120 |
Why?
|
| Dementia | 3 | 1999 | 213 | 0.120 |
Why?
|
| Genomic Imprinting | 2 | 2010 | 32 | 0.120 |
Why?
|
| Inflammation | 1 | 2012 | 1049 | 0.120 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2009 | 1518 | 0.120 |
Why?
|
| Amantadine | 3 | 2007 | 17 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2011 | 958 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 1447 | 0.120 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1995 | 10 | 0.110 |
Why?
|
| Asia | 2 | 2008 | 108 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 156 | 0.110 |
Why?
|
| Sampling Studies | 4 | 2008 | 74 | 0.110 |
Why?
|
| Geese | 2 | 2009 | 7 | 0.110 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1995 | 36 | 0.110 |
Why?
|
| Physicians | 2 | 2013 | 668 | 0.110 |
Why?
|
| Amyloid | 1 | 1996 | 104 | 0.110 |
Why?
|
| Mothers | 2 | 2010 | 142 | 0.110 |
Why?
|
| Hypertension, Portal | 1 | 1995 | 44 | 0.110 |
Why?
|
| Disease Models, Animal | 8 | 2013 | 2479 | 0.110 |
Why?
|
| Genes, Regulator | 3 | 1989 | 59 | 0.110 |
Why?
|
| Sequence Alignment | 3 | 2009 | 348 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2007 | 453 | 0.110 |
Why?
|
| Heterozygote | 5 | 2007 | 381 | 0.110 |
Why?
|
| Parents | 3 | 2012 | 292 | 0.110 |
Why?
|
| Glucose | 5 | 2012 | 686 | 0.110 |
Why?
|
| Monosaccharide Transport Proteins | 3 | 1990 | 76 | 0.110 |
Why?
|
| Nedocromil | 1 | 2014 | 6 | 0.110 |
Why?
|
| Serologic Tests | 2 | 2008 | 40 | 0.110 |
Why?
|
| Lung | 5 | 2014 | 1359 | 0.110 |
Why?
|
| Survival Rate | 4 | 2013 | 1945 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 795 | 0.110 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 184 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2012 | 537 | 0.110 |
Why?
|
| Russia | 3 | 2013 | 28 | 0.110 |
Why?
|
| Reference Values | 6 | 2009 | 603 | 0.100 |
Why?
|
| Mites | 1 | 2004 | 17 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2002 | 123 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2012 | 1129 | 0.100 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 136 | 0.100 |
Why?
|
| Protein Binding | 4 | 2013 | 1526 | 0.100 |
Why?
|
| Cloning, Molecular | 5 | 2011 | 577 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1703 | 0.100 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2011 | 726 | 0.100 |
Why?
|
| Etoposide | 2 | 2011 | 205 | 0.100 |
Why?
|
| Genetics, Behavioral | 1 | 1993 | 22 | 0.100 |
Why?
|
| Mesothelioma | 2 | 2011 | 331 | 0.100 |
Why?
|
| Ice Cover | 1 | 2013 | 2 | 0.100 |
Why?
|
| DNA Probes | 3 | 1990 | 66 | 0.100 |
Why?
|
| Hemagglutinins | 2 | 2011 | 22 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 557 | 0.100 |
Why?
|
| Genetics, Medical | 2 | 2009 | 51 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2008 | 40 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2014 | 93 | 0.100 |
Why?
|
| Germany | 5 | 2007 | 81 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2011 | 61 | 0.100 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2013 | 3 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2013 | 78 | 0.100 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2013 | 69 | 0.100 |
Why?
|
| Clusterin | 1 | 2013 | 13 | 0.100 |
Why?
|
| Endoscopy | 1 | 1997 | 366 | 0.100 |
Why?
|
| Sialic Acids | 2 | 2010 | 17 | 0.100 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1993 | 8 | 0.100 |
Why?
|
| Bronchi | 2 | 2012 | 224 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2003 | 26 | 0.100 |
Why?
|
| Cyclins | 1 | 2013 | 80 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2013 | 98 | 0.100 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2003 | 23 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1995 | 239 | 0.100 |
Why?
|
| Climate Change | 1 | 2013 | 61 | 0.090 |
Why?
|
| Adiposity | 1 | 2013 | 75 | 0.090 |
Why?
|
| Age of Onset | 4 | 2007 | 341 | 0.090 |
Why?
|
| SAP90-PSD95 Associated Proteins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Siblings | 3 | 2014 | 108 | 0.090 |
Why?
|
| Duodenitis | 1 | 1992 | 3 | 0.090 |
Why?
|
| Cytarabine | 1 | 2013 | 217 | 0.090 |
Why?
|
| Microsatellite Repeats | 4 | 2002 | 150 | 0.090 |
Why?
|
| Gallstones | 1 | 1992 | 21 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2003 | 52 | 0.090 |
Why?
|
| Apoptosis | 3 | 2013 | 1719 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2012 | 80 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2003 | 173 | 0.090 |
Why?
|
| International Cooperation | 1 | 2012 | 132 | 0.090 |
Why?
|
| Virus Shedding | 3 | 2011 | 19 | 0.090 |
Why?
|
| Fasting | 3 | 2013 | 164 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 90 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2012 | 124 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 266 | 0.090 |
Why?
|
| Rimantadine | 2 | 2007 | 8 | 0.090 |
Why?
|
| C-Peptide | 3 | 2013 | 184 | 0.090 |
Why?
|
| HN Protein | 1 | 2001 | 4 | 0.090 |
Why?
|
| Genealogy and Heraldry | 1 | 2011 | 13 | 0.090 |
Why?
|
| Virus Cultivation | 3 | 2011 | 14 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 67 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2014 | 752 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2004 | 235 | 0.090 |
Why?
|
| Disease Transmission, Infectious | 1 | 2002 | 56 | 0.080 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 91 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 172 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 99 | 0.080 |
Why?
|
| Asia, Southeastern | 2 | 2008 | 18 | 0.080 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2011 | 66 | 0.080 |
Why?
|
| Proteins | 3 | 2012 | 790 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2012 | 478 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2012 | 207 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 39 | 0.080 |
Why?
|
| Viral Matrix Proteins | 2 | 2011 | 13 | 0.080 |
Why?
|
| Conserved Sequence | 3 | 2006 | 209 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 56 | 0.080 |
Why?
|
| Consanguinity | 4 | 2005 | 72 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 78 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2011 | 83 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 1990 | 40 | 0.080 |
Why?
|
| Gene-Environment Interaction | 1 | 2011 | 120 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 302 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2012 | 524 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 109 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2010 | 45 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2012 | 476 | 0.080 |
Why?
|
| DNA Restriction Enzymes | 7 | 1991 | 76 | 0.080 |
Why?
|
| Evolution, Molecular | 3 | 2011 | 877 | 0.080 |
Why?
|
| Respiratory System | 3 | 2013 | 117 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2011 | 672 | 0.080 |
Why?
|
| Antithrombin III | 1 | 1989 | 9 | 0.080 |
Why?
|
| Logistic Models | 2 | 2011 | 1240 | 0.080 |
Why?
|
| Introns | 3 | 2012 | 298 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2011 | 1260 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 874 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2013 | 709 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2014 | 9070 | 0.080 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1989 | 29 | 0.080 |
Why?
|
| Isoantigens | 1 | 2009 | 72 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 298 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2011 | 200 | 0.070 |
Why?
|
| Pregnancy Outcome | 2 | 2012 | 267 | 0.070 |
Why?
|
| Matched-Pair Analysis | 3 | 2002 | 40 | 0.070 |
Why?
|
| Family Health | 4 | 2003 | 154 | 0.070 |
Why?
|
| Genes, Dominant | 2 | 1996 | 111 | 0.070 |
Why?
|
| Cold Temperature | 3 | 2003 | 159 | 0.070 |
Why?
|
| Monoamine Oxidase | 1 | 2009 | 24 | 0.070 |
Why?
|
| Capital Financing | 1 | 1999 | 4 | 0.070 |
Why?
|
| Social Behavior Disorders | 1 | 2009 | 20 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2007 | 1909 | 0.070 |
Why?
|
| Acclimatization | 3 | 2003 | 88 | 0.070 |
Why?
|
| DNA Probes, HLA | 1 | 1988 | 2 | 0.070 |
Why?
|
| Apolipoproteins B | 1 | 1988 | 36 | 0.070 |
Why?
|
| Protein Structure, Quaternary | 1 | 2009 | 100 | 0.070 |
Why?
|
| Cost of Illness | 4 | 2010 | 158 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2011 | 601 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 827 | 0.070 |
Why?
|
| Peptide Library | 1 | 2009 | 84 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 798 | 0.070 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 41 | 0.070 |
Why?
|
| Finland | 2 | 2006 | 31 | 0.070 |
Why?
|
| Gangliosides | 1 | 2008 | 9 | 0.070 |
Why?
|
| Spleen | 1 | 2009 | 372 | 0.070 |
Why?
|
| Health Services | 1 | 1999 | 53 | 0.070 |
Why?
|
| Brain | 2 | 2009 | 2337 | 0.070 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 1988 | 32 | 0.070 |
Why?
|
| Somatomedins | 2 | 1988 | 28 | 0.070 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 17 | 0.070 |
Why?
|
| Monte Carlo Method | 3 | 1994 | 192 | 0.070 |
Why?
|
| Oceania | 1 | 2008 | 5 | 0.070 |
Why?
|
| Thailand | 2 | 2013 | 66 | 0.070 |
Why?
|
| Recombination, Genetic | 5 | 2005 | 420 | 0.070 |
Why?
|
| Iodide Peroxidase | 2 | 1999 | 215 | 0.070 |
Why?
|
| South America | 1 | 2008 | 35 | 0.070 |
Why?
|
| Neutrophils | 1 | 2009 | 324 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 371 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 1995 | 1193 | 0.070 |
Why?
|
| Christianity | 3 | 2001 | 36 | 0.070 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 75 | 0.070 |
Why?
|
| HMGB2 Protein | 1 | 2008 | 4 | 0.070 |
Why?
|
| High Mobility Group Proteins | 1 | 2008 | 27 | 0.070 |
Why?
|
| Population | 1 | 2008 | 36 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 810 | 0.070 |
Why?
|
| Respite Care | 2 | 1997 | 8 | 0.070 |
Why?
|
| Vitamin K Epoxide Reductases | 2 | 2013 | 16 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2013 | 20 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 295 | 0.070 |
Why?
|
| tau Proteins | 1 | 2008 | 97 | 0.070 |
Why?
|
| HeLa Cells | 1 | 2009 | 517 | 0.070 |
Why?
|
| Molecular Chaperones | 1 | 2008 | 124 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 825 | 0.070 |
Why?
|
| 3' Untranslated Regions | 2 | 2012 | 98 | 0.070 |
Why?
|
| Marriage | 1 | 1997 | 23 | 0.070 |
Why?
|
| Health Expenditures | 1 | 1999 | 98 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 984 | 0.070 |
Why?
|
| HapMap Project | 2 | 2012 | 47 | 0.070 |
Why?
|
| Child Language | 1 | 1997 | 6 | 0.070 |
Why?
|
| Coronary Disease | 1 | 1988 | 221 | 0.070 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 520 | 0.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2009 | 175 | 0.060 |
Why?
|
| Age Distribution | 3 | 2009 | 206 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2008 | 95 | 0.060 |
Why?
|
| Quality Control | 2 | 2014 | 123 | 0.060 |
Why?
|
| Chromosome Segregation | 2 | 2004 | 35 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2007 | 212 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2012 | 3814 | 0.060 |
Why?
|
| Asbestos | 2 | 2011 | 20 | 0.060 |
Why?
|
| Proinsulin | 1 | 2007 | 123 | 0.060 |
Why?
|
| Forecasting | 1 | 2008 | 288 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2012 | 699 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2007 | 133 | 0.060 |
Why?
|
| Financial Management | 1 | 1997 | 21 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2011 | 334 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 244 | 0.060 |
Why?
|
| Military Medicine | 1 | 1997 | 24 | 0.060 |
Why?
|
| Speech Disorders | 2 | 1993 | 17 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 63 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2006 | 36 | 0.060 |
Why?
|
| Washington | 1 | 2006 | 49 | 0.060 |
Why?
|
| Virulence Factors | 1 | 2007 | 113 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2008 | 4546 | 0.060 |
Why?
|
| Indians, North American | 2 | 2011 | 48 | 0.060 |
Why?
|
| Lysine | 1 | 2008 | 182 | 0.060 |
Why?
|
| Virion | 2 | 1995 | 61 | 0.060 |
Why?
|
| HLA-DQ Antigens | 2 | 1991 | 51 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 95 | 0.060 |
Why?
|
| Recurrence | 3 | 2012 | 1188 | 0.060 |
Why?
|
| Patient Admission | 1 | 1997 | 118 | 0.060 |
Why?
|
| Cross Reactions | 3 | 2012 | 110 | 0.060 |
Why?
|
| Transfection | 3 | 2011 | 877 | 0.060 |
Why?
|
| DNA, Viral | 4 | 1999 | 234 | 0.060 |
Why?
|
| Chicago | 2 | 2013 | 1452 | 0.060 |
Why?
|
| Macular Degeneration | 1 | 1996 | 44 | 0.060 |
Why?
|
| Neuregulin-1 | 1 | 2006 | 17 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2001 | 69 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 473 | 0.060 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2005 | 7 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2006 | 72 | 0.060 |
Why?
|
| Crohn Disease | 1 | 1992 | 808 | 0.060 |
Why?
|
| Community Health Centers | 1 | 1997 | 119 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2013 | 312 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2011 | 422 | 0.060 |
Why?
|
| Protein Folding | 1 | 2007 | 291 | 0.060 |
Why?
|
| Cognition | 1 | 2010 | 625 | 0.060 |
Why?
|
| Quality of Life | 1 | 2004 | 1776 | 0.060 |
Why?
|
| Viral Vaccines | 2 | 2002 | 37 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1098 | 0.060 |
Why?
|
| NADP | 2 | 2003 | 48 | 0.060 |
Why?
|
| Mitochondria | 2 | 2013 | 612 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 1996 | 379 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2006 | 236 | 0.050 |
Why?
|
| Muscles | 2 | 2012 | 177 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2011 | 300 | 0.050 |
Why?
|
| Web Browser | 1 | 2014 | 5 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 647 | 0.050 |
Why?
|
| Hospitalization | 3 | 2013 | 924 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2007 | 504 | 0.050 |
Why?
|
| Gastric Bypass | 1 | 2006 | 114 | 0.050 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2004 | 22 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 147 | 0.050 |
Why?
|
| Mathematics | 4 | 1997 | 178 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2014 | 81 | 0.050 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 83 | 0.050 |
Why?
|
| Prevalence | 3 | 2010 | 1318 | 0.050 |
Why?
|
| Twins, Monozygotic | 1 | 2014 | 58 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1071 | 0.050 |
Why?
|
| Prognosis | 3 | 2012 | 3890 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 2 | 2013 | 240 | 0.050 |
Why?
|
| Simvastatin | 1 | 2014 | 106 | 0.050 |
Why?
|
| Diagnosis | 1 | 2013 | 17 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 207 | 0.050 |
Why?
|
| Cell Count | 1 | 2014 | 195 | 0.050 |
Why?
|
| Pharmacokinetics | 1 | 2013 | 10 | 0.050 |
Why?
|
| Swine Diseases | 1 | 2013 | 15 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 603 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2003 | 944 | 0.050 |
Why?
|
| Bacterial Proteins | 2 | 1991 | 878 | 0.050 |
Why?
|
| Africa | 3 | 2007 | 109 | 0.050 |
Why?
|
| Language Development Disorders | 1 | 1993 | 24 | 0.050 |
Why?
|
| RNA Isoforms | 1 | 2012 | 5 | 0.050 |
Why?
|
| Meat | 1 | 2003 | 27 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2013 | 154 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 246 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2012 | 42 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2014 | 416 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2013 | 122 | 0.050 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 77 | 0.050 |
Why?
|
| Protein Conformation | 2 | 2012 | 907 | 0.050 |
Why?
|
| China | 4 | 2009 | 264 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2012 | 2787 | 0.050 |
Why?
|
| Receptors, Adiponectin | 1 | 2012 | 4 | 0.050 |
Why?
|
| Resistin | 1 | 2012 | 12 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2013 | 187 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 3 | 2013 | 10 | 0.050 |
Why?
|
| Receptors, Leptin | 1 | 2012 | 33 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2004 | 229 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2012 | 88 | 0.040 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 1992 | 10 | 0.040 |
Why?
|
| Students | 1 | 2013 | 177 | 0.040 |
Why?
|
| Random Allocation | 1 | 2012 | 308 | 0.040 |
Why?
|
| Public Health | 1 | 2013 | 152 | 0.040 |
Why?
|
| Acute Disease | 2 | 1997 | 838 | 0.040 |
Why?
|
| Deoxyglucose | 1 | 2001 | 38 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2012 | 279 | 0.040 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1991 | 17 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2002 | 52 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2001 | 166 | 0.040 |
Why?
|
| Metabolomics | 1 | 2012 | 98 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2001 | 142 | 0.040 |
Why?
|
| Deoxycytidine Kinase | 1 | 2011 | 4 | 0.040 |
Why?
|
| Intracellular Membranes | 1 | 2001 | 112 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2011 | 27 | 0.040 |
Why?
|
| Cytogenetics | 1 | 2011 | 27 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1991 | 38 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2011 | 77 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2008 | 351 | 0.040 |
Why?
|
| Radiation Effects | 1 | 2011 | 25 | 0.040 |
Why?
|
| Zeolites | 1 | 2011 | 4 | 0.040 |
Why?
|
| Cocarcinogenesis | 1 | 2011 | 11 | 0.040 |
Why?
|
| Carcinogens, Environmental | 1 | 2011 | 7 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2013 | 309 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 885 | 0.040 |
Why?
|
| Models, Theoretical | 2 | 2014 | 494 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 35 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 300 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2014 | 2434 | 0.040 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2000 | 27 | 0.040 |
Why?
|
| Quail | 1 | 2000 | 8 | 0.040 |
Why?
|
| Bird Diseases | 1 | 2000 | 8 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2012 | 276 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2001 | 147 | 0.040 |
Why?
|
| Micronucleus, Germline | 1 | 2010 | 3 | 0.040 |
Why?
|
| Interpersonal Relations | 2 | 2004 | 174 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2011 | 79 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2007 | 10128 | 0.040 |
Why?
|
| Principal Component Analysis | 2 | 2011 | 167 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2012 | 43 | 0.040 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2010 | 32 | 0.040 |
Why?
|
| Plasmids | 1 | 2011 | 272 | 0.040 |
Why?
|
| Calcium | 2 | 2003 | 1173 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2001 | 190 | 0.040 |
Why?
|
| Internet | 1 | 2013 | 345 | 0.040 |
Why?
|
| Adipocytes | 1 | 2001 | 169 | 0.040 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2000 | 9 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2010 | 135 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 3 | 2002 | 56 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2012 | 69 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1990 | 85 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2011 | 135 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2012 | 268 | 0.040 |
Why?
|
| Proteomics | 1 | 2012 | 261 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 89 | 0.040 |
Why?
|
| Neurons | 1 | 2008 | 1568 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 336 | 0.040 |
Why?
|
| Perilipin-1 | 1 | 2009 | 7 | 0.040 |
Why?
|
| Reye Syndrome | 1 | 1999 | 16 | 0.040 |
Why?
|
| Cats | 2 | 1990 | 281 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 703 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 888 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2010 | 324 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2011 | 573 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 1999 | 43 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2012 | 696 | 0.040 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 58 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2010 | 91 | 0.040 |
Why?
|
| World Health Organization | 2 | 2012 | 121 | 0.040 |
Why?
|
| Selection, Genetic | 2 | 2005 | 538 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 348 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 1999 | 140 | 0.040 |
Why?
|
| Vietnam | 2 | 2009 | 15 | 0.040 |
Why?
|
| Skin Tests | 2 | 2004 | 46 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2006 | 765 | 0.040 |
Why?
|
| Genome | 1 | 2012 | 407 | 0.040 |
Why?
|
| Environment | 4 | 2009 | 230 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2007 | 144 | 0.040 |
Why?
|
| Patient Selection | 2 | 2009 | 688 | 0.040 |
Why?
|
| Homozygote | 2 | 2005 | 206 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1991 | 424 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1993 | 125 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 441 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 688 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 364 | 0.040 |
Why?
|
| Genetic Phenomena | 1 | 2008 | 6 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2008 | 158 | 0.030 |
Why?
|
| Genetic Privacy | 1 | 2008 | 12 | 0.030 |
Why?
|
| Isotopes | 1 | 2008 | 26 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2008 | 392 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2009 | 187 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 1996 | 360 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 2 | 2008 | 23 | 0.030 |
Why?
|
| Confidentiality | 1 | 2008 | 75 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 1849 | 0.030 |
Why?
|
| Biomarkers | 2 | 2011 | 1905 | 0.030 |
Why?
|
| Cricetinae | 2 | 1995 | 532 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2009 | 174 | 0.030 |
Why?
|
| HIV-1 | 1 | 1999 | 173 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2003 | 3431 | 0.030 |
Why?
|
| Medical Records | 1 | 2008 | 121 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1114 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 451 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2007 | 31 | 0.030 |
Why?
|
| Contraindications | 2 | 2010 | 65 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 74 | 0.030 |
Why?
|
| International Agencies | 1 | 2007 | 34 | 0.030 |
Why?
|
| Endoscopes | 1 | 1997 | 10 | 0.030 |
Why?
|
| United Kingdom | 2 | 2002 | 189 | 0.030 |
Why?
|
| Adherens Junctions | 1 | 2007 | 34 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2004 | 494 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1908 | 0.030 |
Why?
|
| Apolipoproteins A | 1 | 1996 | 10 | 0.030 |
Why?
|
| Apolipoprotein C-III | 1 | 1996 | 8 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1987 | 155 | 0.030 |
Why?
|
| Haploidy | 1 | 1996 | 30 | 0.030 |
Why?
|
| Gene Library | 2 | 1996 | 124 | 0.030 |
Why?
|
| Italy | 1 | 1996 | 110 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1992 | 621 | 0.030 |
Why?
|
| Programming Languages | 1 | 2006 | 16 | 0.030 |
Why?
|
| Data Collection | 2 | 1997 | 370 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 1996 | 30 | 0.030 |
Why?
|
| Sequence Tagged Sites | 1 | 1996 | 11 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 42 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 1996 | 63 | 0.030 |
Why?
|
| Genetic Techniques | 2 | 2005 | 74 | 0.030 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 1996 | 25 | 0.030 |
Why?
|
| Minisatellite Repeats | 2 | 2002 | 23 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2008 | 317 | 0.030 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 1995 | 17 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2008 | 291 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 74 | 0.030 |
Why?
|
| Life Tables | 1 | 1995 | 46 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 1995 | 68 | 0.030 |
Why?
|
| Homeostasis | 2 | 2002 | 459 | 0.030 |
Why?
|
| Informed Consent | 1 | 2008 | 276 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 2 | 2001 | 61 | 0.030 |
Why?
|
| Mice, Obese | 1 | 1995 | 49 | 0.030 |
Why?
|
| Biometry | 3 | 1997 | 70 | 0.030 |
Why?
|
| Luciferases | 1 | 2005 | 128 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 1995 | 71 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2008 | 328 | 0.030 |
Why?
|
| Binding Sites | 2 | 2013 | 1126 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2001 | 228 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2000 | 30 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1995 | 53 | 0.030 |
Why?
|
| Jews | 1 | 1995 | 42 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 1995 | 85 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2005 | 275 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1130 | 0.030 |
Why?
|
| Hyperthyroxinemia | 1 | 1995 | 17 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2000 | 60 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 1997 | 154 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1995 | 281 | 0.030 |
Why?
|
| Thimerosal | 1 | 2004 | 6 | 0.030 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2004 | 9 | 0.030 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2004 | 11 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 124 | 0.030 |
Why?
|
| Budesonide | 1 | 2014 | 46 | 0.030 |
Why?
|
| Probability | 2 | 1986 | 352 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 8 | 0.030 |
Why?
|
| Testosterone | 1 | 2005 | 258 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2004 | 61 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 543 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 28 | 0.030 |
Why?
|
| Primates | 1 | 2005 | 158 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
| Antarctic Regions | 1 | 2013 | 10 | 0.030 |
Why?
|
| Pacific Ocean | 1 | 2013 | 19 | 0.030 |
Why?
|
| Air | 1 | 2013 | 63 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2013 | 29 | 0.020 |
Why?
|
| Serine Peptidase Inhibitor Kazal-Type 5 | 1 | 2013 | 2 | 0.020 |
Why?
|
| Caribbean Region | 1 | 2013 | 26 | 0.020 |
Why?
|
| Hyperlipoproteinemias | 1 | 2003 | 7 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 134 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 278 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 291 | 0.020 |
Why?
|
| Fear | 1 | 2004 | 87 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 54 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1997 | 1719 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2827 | 0.020 |
Why?
|
| Seawater | 1 | 2013 | 51 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2008 | 2121 | 0.020 |
Why?
|
| Genomic Library | 1 | 1993 | 30 | 0.020 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2002 | 8 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 1993 | 66 | 0.020 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.020 |
Why?
|
| Control Groups | 1 | 2002 | 16 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2004 | 170 | 0.020 |
Why?
|
| Language Development | 1 | 1983 | 22 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 296 | 0.020 |
Why?
|
| Glycogen Phosphorylase | 1 | 2012 | 6 | 0.020 |
Why?
|
| Biotransformation | 1 | 2012 | 46 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 217 | 0.020 |
Why?
|
| Karyotyping | 1 | 1993 | 220 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 80 | 0.020 |
Why?
|
| Computer Graphics | 1 | 2003 | 99 | 0.020 |
Why?
|
| Cytosol | 1 | 1993 | 192 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2002 | 56 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 55 | 0.020 |
Why?
|
| Haplorhini | 1 | 2002 | 77 | 0.020 |
Why?
|
| Ireland | 1 | 2002 | 12 | 0.020 |
Why?
|
| Body Constitution | 1 | 2002 | 26 | 0.020 |
Why?
|
| Incidence | 2 | 2006 | 1697 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2012 | 70 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2004 | 73 | 0.020 |
Why?
|
| Social Support | 1 | 2004 | 231 | 0.020 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 11 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2011 | 7 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 1996 | 119 | 0.020 |
Why?
|
| Protein Transport | 1 | 2013 | 438 | 0.020 |
Why?
|
| Data Mining | 1 | 2011 | 44 | 0.020 |
Why?
|
| Capecitabine | 1 | 2012 | 97 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1171 | 0.020 |
Why?
|
| Virus Physiological Phenomena | 1 | 2011 | 7 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2011 | 53 | 0.020 |
Why?
|
| Anxiety | 1 | 2004 | 336 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 196 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2011 | 51 | 0.020 |
Why?
|
| Catheterization | 1 | 1992 | 217 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 64 | 0.020 |
Why?
|
| DNA Replication | 1 | 2002 | 168 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2002 | 359 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 1991 | 26 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 288 | 0.020 |
Why?
|
| South Dakota | 1 | 2000 | 47 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1160 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.020 |
Why?
|
| Viruses | 1 | 2011 | 64 | 0.020 |
Why?
|
| Immunization Programs | 1 | 2010 | 26 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 737 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1991 | 147 | 0.020 |
Why?
|
| Aging | 2 | 2008 | 725 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 252 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 1990 | 58 | 0.020 |
Why?
|
| Emotions | 1 | 2004 | 368 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2000 | 7 | 0.020 |
Why?
|
| Epinephrine | 1 | 1990 | 92 | 0.020 |
Why?
|
| Cerebellum | 1 | 2012 | 247 | 0.020 |
Why?
|
| Thrombin Time | 1 | 1989 | 4 | 0.020 |
Why?
|
| Artifacts | 1 | 2001 | 241 | 0.020 |
Why?
|
| Prothrombin Time | 1 | 1989 | 18 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 1989 | 17 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2011 | 257 | 0.020 |
Why?
|
| Fibrinogen | 1 | 1989 | 48 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1989 | 31 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 100 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2010 | 56 | 0.020 |
Why?
|
| HIV Infections | 1 | 1999 | 952 | 0.020 |
Why?
|
| Influenza A Virus, H5N2 Subtype | 1 | 2009 | 3 | 0.020 |
Why?
|
| Nigeria | 1 | 2000 | 162 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 1002 | 0.020 |
Why?
|
| Platelet Count | 1 | 1989 | 90 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 1581 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 136 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2010 | 87 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 98 | 0.020 |
Why?
|
| Arginine | 1 | 2009 | 140 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2009 | 135 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 354 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2010 | 130 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2001 | 179 | 0.020 |
Why?
|
| Serotonin | 1 | 1990 | 209 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 561 | 0.020 |
Why?
|
| Apolipoproteins | 1 | 1989 | 34 | 0.020 |
Why?
|
| Topography, Medical | 1 | 2008 | 5 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 1988 | 30 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 194 | 0.020 |
Why?
|
| Gangliosidosis, GM1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Porcine Reproductive and Respiratory Syndrome | 1 | 2008 | 2 | 0.020 |
Why?
|
| Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
| Color Perception | 1 | 1990 | 119 | 0.020 |
Why?
|
| Collagen | 1 | 1990 | 301 | 0.020 |
Why?
|
| Campylobacter jejuni | 1 | 2008 | 14 | 0.020 |
Why?
|
| Glycolipids | 1 | 2008 | 26 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 26 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2008 | 7 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2008 | 48 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 75 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 291 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 804 | 0.020 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2008 | 2 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 367 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Polyubiquitin | 1 | 2008 | 8 | 0.020 |
Why?
|
| Sulfurtransferases | 1 | 1988 | 4 | 0.020 |
Why?
|
| Receptor, trkA | 1 | 2008 | 12 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 98 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 753 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 256 | 0.020 |
Why?
|
| Wisconsin | 1 | 2008 | 44 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2009 | 111 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 368 | 0.020 |
Why?
|
| Kidney | 1 | 1993 | 1093 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2008 | 169 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 653 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 1989 | 224 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 186 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 87 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1999 | 774 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 109 | 0.020 |
Why?
|
| Oxazines | 1 | 2007 | 15 | 0.020 |
Why?
|
| Xanthenes | 1 | 2007 | 21 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 232 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 23 | 0.020 |
Why?
|
| Speech-Language Pathology | 1 | 1997 | 5 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 337 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2007 | 139 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2008 | 127 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 1988 | 214 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 140 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1988 | 149 | 0.020 |
Why?
|
| DNA, Recombinant | 2 | 1996 | 60 | 0.020 |
Why?
|
| Galactose | 1 | 2007 | 27 | 0.020 |
Why?
|
| Glycoconjugates | 1 | 2007 | 11 | 0.020 |
Why?
|
| Rats | 2 | 2008 | 4028 | 0.020 |
Why?
|
| Transportation | 1 | 1997 | 20 | 0.020 |
Why?
|
| Melanoma | 1 | 2011 | 494 | 0.020 |
Why?
|
| Fees and Charges | 1 | 1997 | 14 | 0.020 |
Why?
|
| Economic Competition | 1 | 1997 | 12 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 1997 | 24 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 2 | 1996 | 30 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 2 | 1996 | 34 | 0.020 |
Why?
|
| Markov Chains | 1 | 1997 | 137 | 0.020 |
Why?
|
| Oncogenes | 1 | 2007 | 100 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1997 | 2562 | 0.020 |
Why?
|
| Health Care Costs | 1 | 1999 | 248 | 0.020 |
Why?
|
| Exercise | 1 | 2010 | 353 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 378 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 1997 | 54 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 2 | 1996 | 80 | 0.020 |
Why?
|
| Nose | 1 | 2007 | 95 | 0.020 |
Why?
|
| Income | 1 | 1997 | 86 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2006 | 45 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 302 | 0.010 |
Why?
|
| Intestines | 1 | 2009 | 433 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 2006 | 24 | 0.010 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2006 | 26 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 916 | 0.010 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 20 | 0.010 |
Why?
|
| Denmark | 1 | 1995 | 19 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 1997 | 278 | 0.010 |
Why?
|
| Biological Assay | 1 | 2006 | 82 | 0.010 |
Why?
|
| Pennsylvania | 1 | 1986 | 105 | 0.010 |
Why?
|
| Species Specificity | 2 | 2000 | 683 | 0.010 |
Why?
|
| Trypsin | 1 | 2005 | 90 | 0.010 |
Why?
|
| Thyroxine | 2 | 1995 | 386 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 1997 | 191 | 0.010 |
Why?
|
| Allantois | 1 | 1995 | 3 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 1611 | 0.010 |
Why?
|
| Codon | 1 | 1995 | 116 | 0.010 |
Why?
|
| Color Vision Defects | 1 | 1985 | 22 | 0.010 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1985 | 15 | 0.010 |
Why?
|
| HLA-G Antigens | 1 | 2004 | 52 | 0.010 |
Why?
|
| Poisson Distribution | 1 | 2004 | 47 | 0.010 |
Why?
|
| Adenosine Triphosphate | 2 | 1996 | 312 | 0.010 |
Why?
|
| X Chromosome | 1 | 1985 | 154 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 67 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2005 | 178 | 0.010 |
Why?
|
| Hemagglutination, Viral | 2 | 1984 | 4 | 0.010 |
Why?
|
| Morbidity | 1 | 2004 | 162 | 0.010 |
Why?
|
| Medicaid | 1 | 1997 | 245 | 0.010 |
Why?
|
| Eggs | 1 | 1993 | 13 | 0.010 |
Why?
|
| Speech Production Measurement | 1 | 1993 | 9 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 373 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 404 | 0.010 |
Why?
|
| Dyslexia | 1 | 1993 | 12 | 0.010 |
Why?
|
| Health Plan Implementation | 1 | 1994 | 62 | 0.010 |
Why?
|
| Dipeptides | 1 | 2003 | 39 | 0.010 |
Why?
|
| Lithium | 1 | 1983 | 61 | 0.010 |
Why?
|
| Alcoholism | 1 | 1985 | 188 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1993 | 79 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 402 | 0.010 |
Why?
|
| Obesity, Morbid | 1 | 2006 | 244 | 0.010 |
Why?
|
| Mood Disorders | 1 | 1983 | 82 | 0.010 |
Why?
|
| Speech | 1 | 1993 | 90 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 199 | 0.010 |
Why?
|
| Pneumonia | 1 | 2004 | 192 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 237 | 0.010 |
Why?
|
| Zoonoses | 1 | 2003 | 28 | 0.010 |
Why?
|
| Rabbits | 1 | 1993 | 579 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2543 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 410 | 0.010 |
Why?
|
| Infection Control | 1 | 2003 | 130 | 0.010 |
Why?
|
| Epidemiologic Methods | 2 | 1989 | 60 | 0.010 |
Why?
|
| Body Weight | 1 | 2003 | 449 | 0.010 |
Why?
|
| Nucleotide Mapping | 1 | 1991 | 5 | 0.010 |
Why?
|
| Hemagglutination Tests | 1 | 1991 | 9 | 0.010 |
Why?
|
| Cross Infection | 1 | 2003 | 149 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2004 | 350 | 0.010 |
Why?
|
| Iodides | 1 | 1991 | 18 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1991 | 40 | 0.010 |
Why?
|
| Autoradiography | 1 | 1990 | 50 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2002 | 87 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2003 | 299 | 0.010 |
Why?
|
| Untranslated Regions | 1 | 2000 | 18 | 0.010 |
Why?
|
| Arizona | 1 | 2000 | 10 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 820 | 0.010 |
Why?
|
| Bronchitis | 1 | 2000 | 7 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 241 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 655 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2000 | 77 | 0.010 |
Why?
|
| Mass Vaccination | 1 | 2000 | 10 | 0.010 |
Why?
|
| Neuropeptides | 1 | 2000 | 113 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2000 | 291 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 303 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2000 | 129 | 0.010 |
Why?
|
| Carrier State | 1 | 2000 | 40 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1991 | 309 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1991 | 280 | 0.010 |
Why?
|
| Viral Nonstructural Proteins | 1 | 1999 | 38 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 183 | 0.010 |
Why?
|
| Goiter | 1 | 1999 | 45 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1991 | 361 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1999 | 73 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1990 | 422 | 0.010 |
Why?
|
| Viremia | 1 | 1999 | 51 | 0.010 |
Why?
|
| Congenital Hypothyroidism | 1 | 1999 | 80 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 1999 | 196 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 1172 | 0.010 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2000 | 284 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 1999 | 193 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1999 | 275 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 1996 | 144 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 1995 | 37 | 0.010 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1995 | 32 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1995 | 287 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 37 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1984 | 16 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1996 | 302 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 1022 | 0.010 |
Why?
|
| Speech Therapy | 1 | 1983 | 9 | 0.010 |
Why?
|
| Photometry | 1 | 1990 | 12 | 0.000 |
Why?
|
| Vision Tests | 1 | 1990 | 20 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1980 | 97 | 0.000 |
Why?
|
| Light | 1 | 1990 | 286 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 181 | 0.000 |
Why?
|
| Arylsulfotransferase | 1 | 1988 | 4 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1990 | 883 | 0.000 |
Why?
|
| Hospitals, Psychiatric | 1 | 1983 | 23 | 0.000 |
Why?
|
| Epitopes | 1 | 1983 | 249 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1983 | 235 | 0.000 |
Why?
|